NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

Download real time

1095.70 4.10 (0.38%)

30.13% Fall from 52W High

813.9K NSE+BSE Volume

NSE 17 Sep, 2025 3:54 PM (IST)

63,638.4

Market Cap

High in industry

1.0

Beta 1Year

Average volatility

Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

01 Jun 2021

1095.70

0.38%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

We expect revenue and PAT CAGR of 9.6% and 13.9% over the period FY20-FY23E and recommend 'BUY' with TP of Rs 1,100/share.

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

01 Jun 2021

1095.70

0.38%

Higher R&D; spend offsets benefit of better operating leverage

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

Aurobindo Pharma (ARBP) delivered an operationally in line 4QFY21. The outlook for the Injectables segment continues to improve on the back of better traction in existing products, new introductions, and healthy pipeline build-up comprising complex products. The Vaccine space remains...

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

01 Jun 2021

1095.70

0.38%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

ICICI Securities Limited

Q4 operational performance was below I-direct estimates amid decline across US, Europe and RoW markets. Quarterly gyrations notwithstanding, Aurobindo has one of the most enduring generics ecosystems among peers (vertically integrated model, lower product concentration) to withstand volatility in the US and other generics space. It has also significantly improved its net debt position from foregoing the Sandoz deal and the recent sale of the Natrol business. This also bodes well as the company plans to venture into complex areas like biosimilars, vaccines and complex...

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1129.3

Aurobindo Pharma Ltd.

11 Mar 2021

1095.70

0.38%

According to total sales audit data from IMS, Indian Pharma Market (IPM) grew 2.6% YoY in...

Buy: Aurobindo Pharma Ltd.

Target

Emkay

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1090.5

Aurobindo Pharma Ltd.

16 Feb 2021, 12:00AM

1095.70

0.38%

Monthly Update - IPM grapple for normalized growth after COVID

Accumulate: Aurobindo Pharma Ltd.

Prabhudas Lilladhar

IPM is struggling for growth above 10% even after MoM abating COVID concerns and with MRs, physician activities almost reaching pre-COVID level. We believe key reasons for growth below par are (i) subdued new prescription (Rx) leading to volume de-growth (ii) digital marketing yield going south and (iii) sustained lower demand of acute products. Cardiac and anti-diabetic growth takes a breather in Jan-21 at 8.8% and 5.3% after reporting double digit growth in most months during lockdown. While amongst top therapies Gastro and VMN reported double digit growth of 14%...

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1129.3

Aurobindo Pharma Ltd.

15 Feb 2021

1095.70

0.38%

AUROBINDO PHARMA LTD

Buy: Aurobindo Pharma Ltd.

Target

Geojit BNP Paribas

EBITDA grew 13.3% YoY, EBITDA margin expanded 100bps to 21.5% mainly due to increased gross margin (+60bps YoY), and partially offset by higher R&D; spends. Net profit surged 4x YoY, on account of...

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1129.3

Aurobindo Pharma Ltd.

12 Feb 2021

1095.70

0.38%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

We expect revenue and PAT CAGR of 9.6% and 13.9% over the period FY20-FY23E and recommend Buy with TP of Rs 1,030.

Aurobindo Pharma Ltd. has lost -29.94% in the last 1 Year

Aurobindo Pharma Ltd.

11 Feb 2021

1095.70

0.38%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

Adjusting for certain one-off exceptional items, Q3 results were in line with I-direct estimates on all fronts. Aurobindo has one of the most enduring generics ecosystems among peers (vertically integrated model, lower product concentration) to withstand volatility in the US and other generics space. It has also significantly improved its net debt position from foregoing the Sandoz deal and from the recent sale of Natrol business. This also bodes well as the company plans to venture into complex areas like biosimilars, vaccines and complex injectables where capital requirements are higher and...

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1090.5

Aurobindo Pharma Ltd.

11 Feb 2021

1095.70

0.38%

Q3FY21 Result Update - Product mix to shift towards injectable and specialty; Upgrade to Accumulate

Accumulate: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

CAPA completed for Unit-I, IX, VII and XI. Awaiting USFDA inspection. We upgrade ARBP rating to Accumulate (earlier Hold) as we increase the multiple assigned on FY23E to 15x (PE) v/s earlier 13x. This multiple re-rating...

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1129.3

Aurobindo Pharma Ltd.

21 Dec 2020

1095.70

0.38%

Company Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

Aurobindo Pharma Ltd (ARBP) ABRP has witnessed strong growth in different business verticals like Injectables, ARV, API and Growthmatkets. ABRP has planned to incur capex of USD$ 180mn - USD$ 200mn in Injectibles and Biosimilars to drive growth in upcoming years.

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1129.3

Is Aurobindo Pharma Ltd. worth buying?

1257 Votes:

Buy 80.27%

Sell 13.76%

Hold 5.97%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf